| DC72235 |
Aldometanib |
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis. |
|
| DC72738 |
YLF-466D
Featured
|
YLF-466D is an AMPK activator that inhibits platelet aggregation with IC50 of 84 μM. |
|
| DC72739 |
FAP-PI3KI1 |
FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition. |
|
| DC72740 |
MI 14 |
MI 14 is a selective PI4KIIIβ inhibitor with IC50s of 54 nM, >100 μM, >100 μM for PI4KIIIβ, PI4KIIIα, PI4KIIα, respectively. MI 14 has antiviral activity against HCV 1b, CVB3, HRVM, HVC 2a. |
|
| DC72848 |
Leniolisib phosphate
Featured
|
Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment. |
|
| DC72910 |
CC214-1 |
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study. |
|
| DC74249 |
TAS0612 |
TAS0612 (TAS-0612) is an orally bioavailable multikinase inhibitor of AKT, p70S6K, and p90RSK, inhibits Y-box-binding protein (YBX1) phosphorylation. |
|
| DC74250 |
TCMDC-136364 |
TCMDC-136364 (AKT Kinase Inhibitor) is an Akt kinase inhibitor, selectively inhibits Akt in proliferating cells expressing Trop-2, also potently inhibits P. falciparum multidrug resistant strain Dd2. |
|
| DC74251 |
BI-9774
Featured
|
BI-9774 (BI 9774) is a potent pan-AMPK activator with EC50 of 64 nM in an ADP-Glo kinase assay with human AMPK (α1β1γ1) and EC50 of 8 nM in a cellular GLUT4 translocation assay. |
|
| DC74252 |
KI-301670 |
KI-301670 is a novel potent, specific NUAK1 inhibitor, disturbs NUAK1 signaling by targeting its ATP binding site, effectively inhibits the PI3K/AKT pathway in pancreatic cancer cells. |
|
| DC74253 |
MSG011 |
MSG011 is a potent, pan AMPK isoform activator with EC50 of 140.4 nM, 248.9 nM, 553.4 nM, and 472.9 nM for α1β1γ1, α1β2γ1, α2β1γ1, and α2β2γ1, respectively. |
|
| DC74254 |
PXL770 |
PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation. |
|
| DC74255 |
PXL770 monohydrate potassium salt |
PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation. |
|
| DC74256 |
RX-375 |
RX-375 (RX375) is an indirect small-molecule activator of AMPK by directly binds to Prohibitins (PHB1 and PHB2), induces dissociation of AMPK-PHBs complex. |
|
| DC74257 |
ZLN-024 hydrochloride |
ZLN-024 hydrochloride is a potent, allosteric AMPK activator that has no effect on mitochondrial function or the ADP/ATP ratio, directly activate recombinant AMPK α1β1γ1 and its homologue α2β1γ1 with EC50 of 0.42 uM and 0.95 uM, respectively. |
|
| DC74258 |
NV-5297 |
NV-5297 (NV5297) is a novel small molecule mTORC1 pathway activator, modulates the Sestrin2-Gator2 interaction and activates the mTORC1 pathway in vitro and in vivo. |
|
| DC74259 |
CU05-1189 |
CU05-1189 is a non-peptide, allosteric inhibitor of the pleckstrin homology (PH) domain of PDK1, specifically inhibits Akt signaling pathway. |
|
| DC74260 |
cyclo-CRVLIR
Featured
|
cyclo-CRVLIR is a cyclic peptide that binds selectively to p110α RAS binding domain (p110α-RBD) with ITC Kd of 3 uM, blocks p110α/RAS interaction in vitro and KRAS cancer cell lines. |
|
| DC74261 |
HM5023507 |
HM5023507 is a potemt, selective, orally active dual PI3Kδ/γ inhibitor with IC50 of 4 nM and 5 nM for p110γ and p110δ, respectively. |
|
| DC74262 |
I-229 |
I-229 is a potent and selective inhibitor of Vps34. |
|
| DC74263 |
LL-00071210 |
LL-00071210 is a potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 values of 24.6 nM and 9.4 nM in biochemical and cellular assays, respectively. |
|
| DC74264 |
LL-00084282 |
LL-00084282 is a potent, selective and efficacious dual PI3Kδγ inhibitor with IC50 of 16.26 and 17.45 nM for PI3Kδ and PI3Kγ, respectively. |
|
| DC74265 |
LP-182 |
LP-182 (LP182) is a potent, selective and orally bioavailable multi-functional kinase inhibitor, specifically targets PI3K and MAPK signaling pathways. |
|
| DC74266 |
PF-06862309 |
PF-06862309 (PF-06843195 phosphate ester prodrug) is the in vivo-active, phosphate ester prodrug of PF-06843195, a potent selective PI3Kα inhibitor with Kd of <18 pM. |
|
| DC74267 |
PITCOIN2 |
PITCOIN2 (LU-06-006) is a potent selective PI3KC2α inhibitor with IC50 of 126 nM, has selectivity against PI3KC2γ but shows micromolar activity on PI3KC2β. |
|
| DC74268 |
PITCOIN3 |
PITCOIN3 is a potent, highly selective, cell-permeable inhibitor of PI3KC2α catalytic activity with IC50 of 126 nM. |
|
| DC74269 |
TGX286 |
TGX286 is a potent, selective p110β inhibitor with IC50 of 7, 17 and 13 nM for p110β WT, p110β D862Q, and p110β E858H, respectively, >100-fold selectivity over p110α. |
|
| DC74270 |
GSK-3923868 |
GSK-3923868 (PI4KB inhibitor 30) is a potent, selective, slow-dissociating PI4KB (PI4kIII-beta) inhibitor with pKi of 9.8, >1000-fold selectivity over PI4KA, inhibits HRV viral replication in COPD BECs. |
|
| DC74271 |
HZX-02-059 |
HZX-02-059 is a PIKfyve and tubulin dual-target inhibitor with high affinity for PIKfyve (Kd=10.4 nM), HZX-02-059 is a potent methuosis inducer, shows both in vitro and in vivo anti-tumor activity against TNBC. |
|
| DC74605 |
EDI048 |
EDI048 (compound 1.16) is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis. |
|
